EUVIMEDEUVIMED entdecken
Crossref

Genomic Prostate Score (GPS) as a Prognostic Biomarker in Patients With Localized Prostate Cancer Undergoing Focal Therapy

Sriram Deivasigamani iD, Srinath Kotamarti iD, Mahdi Mottaghi iD, Eric S Adams iD, Alireza Ghoreifi, Hasan Jhaveri, Denis Seguier iD, Michael C Ivey, Joao Paulo Zambon, Anu Podichetty, Thuy Can, Jack Groshopf und 3 weitere

The Prostate · 2026-06 · 86 (9) · 1006-1012

DOI: 10.1002/pros.70175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 08.04.2026. Verfasst von Sriram Deivasigamani und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urologic Surgery, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Focal therapy (FT) encompasses ablation of the prostate cancer (PCa) while preserving the surrounding benign tissue, aiming to minimize or spare patients from postoperative complications. Although FT has been proven effective, the multifocal and heterogeneous nature of PCa is a significant concern regarding the risk of disease progression. The Genomic Prostate Score (GPS) has been shown to aid in the risk stratification of patients with localized disease; however, its role in patients undergoing FT remains unclear. We evaluated the association between the GPS performed on pretreatment biopsy cores and the oncological outcomes of patients with localized PCa treated with FT at our institution.

Methods

This is an institutional review board‐approved retrospective review of a prospectively maintained database of PCa patients undergoing prostate FT at Duke between 2005 and 2020. The study included men with localized PCa, preoperative diagnostic prostate biopsy tissue availability, and a minimum follow‐up of 1‐year. The primary outcome was to evaluate the association between the GPS assay performed on the preoperative prostate biopsy tissue with cumulative incidence of treatment‐failure (TF) defined as requirement of salvage therapy and/or development of metastasis, and prostate cancer‐specific death and failure‐free survival (FFS). The secondary outcome was to assess whether the GPS assay could predict ≥ Gleason Grade Group (GGG) 2 biopsy recurrence/persistence following ablation.

Results

A total of 81 patients met the inclusion criteria. The median follow‐up was 48 months (IQR, 35–98). The median age, preoperative PSA, and PSA density were 74 years (IQR, 68–77), 7.4 ng/ml (IQR, 5.5–10), and 0.19 ng/mL/mL (0.14–0.22), respectively. Of 81 patients, 55 (68%) and 7 (9%) had intermediate and high‐risk disease. The median GPS score was 30 (IQR, 24–40), and 21/81 (26%) had a GPS result > 40. TF and ≥ GGG2 biopsy recurrence were observed in 15/81 (19%) and 10/81 (12%), respectively. GPS was > 40 in 8/15 (53%) and 7/10 (70%) of patients with TF and biopsy recurrence, respectively. On univariable analysis, GPS was significantly associated with TF (HR 1.07, 95% CI, 1.02–1.12, p < 0.01) and biopsy recurrence/persistence (HR 1.09, 95% CI, 1.03–1.15, p = 0.08). Men with GPS of 40–100 were found to be significantly at higher risk of having TF (HR 4.19, 95% CI, 1.26–13.89, p = 0.01) and in‐field biopsy recurrence (HR 14.3, 95% CI, 2.48–82.83, p = 0.003).

Conclusion

Among men treated with focal ablation for localized PCa, the GPS assay appears to be a prognostic indicator of FFS and GGG ≥ 2 biopsy recurrence. Further studies with large sample sizes are required to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMalePrognosisRetrospective StudiesAgedBiomarkers, TumorGenetic Risk ScoreGenomicsProstateMiddle Aged

Stichwörter der Autor:innen

Genomic Prostate Scorebiomarkercryoablationcryotherapyfocal therapyprostate cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urologic Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • IMR, Veteran Affairs Medical System, Durham, North Carolina, USA.
  • Department of Urology, Lille University, Lille, France.
  • Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA.
  • MDX Health, Irvine, California, USA.
  • Exact Sciences Corporation, Madison, Wisconsin, USA.

ORCID-Profile: Sriram Deivasigamani, Srinath Kotamarti, Mahdi Mottaghi, Eric S Adams, Denis Seguier, Thomas J Polascik

Zitieren

APA

Deivasigamani, S., Kotamarti, S., Mottaghi, M., Adams, E. S., Ghoreifi, A., Jhaveri, H., Seguier, D., Ivey, M. C., Zambon, J. P., Podichetty, A., Can, T., Groshopf, J., Gupta, R. T., Moul, J. W., & Polascik, T. J. (2026). Genomic Prostate Score (GPS) as a Prognostic Biomarker in Patients With Localized Prostate Cancer Undergoing Focal Therapy. The Prostate, 86(9), 1006-1012. https://doi.org/10.1002/pros.70175

Vancouver

Deivasigamani S, Kotamarti S, Mottaghi M, Adams ES, Ghoreifi A, Jhaveri H, et al. Genomic Prostate Score (GPS) as a Prognostic Biomarker in Patients With Localized Prostate Cancer Undergoing Focal Therapy. The Prostate. 2026;86(9):1006-1012. doi:10.1002/pros.70175

BibTeX
@article{Deivasigamani2026,
  author = {Deivasigamani, Sriram and Kotamarti, Srinath and Mottaghi, Mahdi and Adams, Eric S and Ghoreifi, Alireza and Jhaveri, Hasan and Seguier, Denis and Ivey, Michael C and Zambon, Joao Paulo and Podichetty, Anu and Can, Thuy and Groshopf, Jack and Gupta, Rajan T and Moul, Judd W and Polascik, Thomas J},
  title = {Genomic Prostate Score (GPS) as a Prognostic Biomarker in Patients With Localized Prostate Cancer Undergoing Focal Therapy},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {9},
  pages = {1006--1012},
  doi = {10.1002/pros.70175}
}
Kostenlos starten →